Melanoma Institute Australia (MIA)
Welcome,         Profile    Billing    Logout  
 12 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Long, Georgina
NADINA, NCT04949113 / 2021-001492-16: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting
3
423
Europe, US, RoW
Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/24
12/28
ABC, NCT02374242 / ACTRN12614001315606: Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Active, not recruiting
2
76
RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016
Melanoma Institute Australia, Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb
Melanoma, Brain Metastases
09/17
12/28
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Active, not recruiting
2
60
RoW
Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda
Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis
Melanoma
01/22
11/24
Neo PeLe, NCT04207086: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Active, not recruiting
2
21
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Melanoma Institute Australia, Merck Sharp & Dohme LLC
Melanoma Stage III
01/23
01/33
Neo-MCC, NCT06151236: Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Recruiting
2
20
RoW
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Merkel Cell Carcinoma
04/26
04/34
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Recruiting
2
218
Europe, RoW
Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy
Melanoma Institute Australia, Bristol-Myers Squibb
Melanoma Stage Iv
08/24
08/25
Neo ReNi II, NCT05418972: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Recruiting
2
20
RoW
Relatlimab and nivolumab fixed dose combination (FDC), Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Stage II Melanoma
12/24
12/34
KEYNOTE-D36, NCT05309421: A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Recruiting
2
90
RoW
EVX-01, Pembrolizumab 25 MG/ML, Keytruda
Evaxion Biotech A/S, Merck Sharp & Dohme LLC
Melanoma Stage III, Melanoma Stage IV
06/25
07/25
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting
2
60
Europe, US, RoW
IO102-IO103, Pembrolizumab KEYTRUDA®
IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC
Melanoma, Squamous Cell Carcinoma of Head and Neck
04/25
01/27
Neo PeLeMM, NCT05545969: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma

Withdrawn
2
44
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Melanoma Institute Australia, Merck Sharp & Dohme LLC
Mucosal Melanoma
05/26
05/36
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
NCT04834973: A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Terminated
1/2
3
RoW
tigilanol tiglate, EBC-46, pembrolizumab, Keytruda
QBiotics Group Limited, Merck Sharp & Dohme LLC
Melanoma
07/22
07/22

Download Options